Defining and Predicting Severe Community-acquired Pneumonia

Overview

Journal Curr Opin Infect Dis

Specialty Infectious Diseases

Date 2010 Jan 7

PMID 20051847

Citations 8

Authors

Samuel M Brown

Nathan C Dean

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Community-acquired pneumonia is a significant clinical and public health problem. Defining and predicting severe pneumonia is difficult but important.

Recent Findings: Several new predictive models and more sophisticated approaches to describing pneumonia severity have been recently proposed, with subsequent validation in varied patient populations. Early data suggest that biomarkers may be useful in the future.

Summary: Definitions of pneumonia severity depend on the relevant clinical or public health question. A health services reference definition seems most useful in most settings. The Infectious Disease Society of America/American Thoracic Society 2007 guidelines and SMART-COP are two recent promising methods for predicting severe pneumonia at the time of presentation. The traditional pneumonia severity index and Confusion Uremia Respiratory rate Blood pressure (CURB)-65 models are less useful. Accurate assessment of severity has important implications for triage, outcome, and defining populations for research applications. Novel biomarkers, while somewhat promising, do not yet have a validated role in pneumonia severity assessment.

Citing Articles

Prognostic value of the platelet, neutrophil, monocyte, basophil, and eosinophil to lymphocyte ratios in patients with severe community-acquired pneumonia (SCAP).

Cui X, Xie B, Zhu K, Liao Q, Zhou J, Du S Sci Rep. 2024; 14(1):30406.

PMID: 39638829 PMC: 11621349. DOI: 10.1038/s41598-024-80727-1.

Prognostic utility of paraspinal muscle index in elderly patients with community-acquired pneumonia.

Lee G, Ko S, Choi H, Hong H, Lee J, Jeong K Clin Exp Emerg Med. 2024; 11(2):171-180.

PMID: 38286501 PMC: 11237258. DOI: 10.15441/ceem.23.142.

Interpretations of the Role of Plasma Albumin in Prognostic Indices: A Literature Review.

Gradel K J Clin Med. 2023; 12(19).

PMID: 37834777 PMC: 10573484. DOI: 10.3390/jcm12196132.

Predictive factors and outcomes of severe community acquired pneumonia in patients with respiratory failure.

Rahat Ullah A, Masood A, Amin S, Ali I Pak J Med Sci. 2022; 38(4Part-II):1031-1037.

PMID: 35634599 PMC: 9121958. DOI: 10.12669/pjms.38.4.5312.

Urea-to-Albumin Ratio and In-Hospital Mortality in Severe Pneumonia Patients.

Tian Y, Li Y, Jiang Z, Chen J Can J Infect Dis Med Microbiol. 2021; 2021:5105870.

PMID: 34721746 PMC: 8556110. DOI: 10.1155/2021/5105870.

References

Leroy O, Santre C, Beuscart C, Georges H, Guery B, Jacquier J . A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. Intensive Care Med. 1995; 21(1):24-31. DOI: 10.1007/BF02425150. View

Baddour L, Yu V, Klugman K, Feldman C, Ortqvist A, Rello J . Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med. 2004; 170(4):440-4. DOI: 10.1164/rccm.200311-1578OC. View

Brown S, Jones B, Jephson A, Dean N . Validation of the Infectious Disease Society of America/American Thoracic Society 2007 guidelines for severe community-acquired pneumonia. Crit Care Med. 2009; 37(12):3010-6. PMC: 2783880. DOI: 10.1097/CCM.0b013e3181b030d9. View

Riley P, Aronsky D, Dean N . Validation of the 2001 American Thoracic Society criteria for severe community-acquired pneumonia. Crit Care Med. 2004; 32(12):2398-402. DOI: 10.1097/01.ccm.0000147443.38234.d2. View

Rello J, Rodriguez A, Lisboa T, Gallego M, Lujan M, Wunderink R . PIRO score for community-acquired pneumonia: a new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia. Crit Care Med. 2008; 37(2):456-62. DOI: 10.1097/CCM.0b013e318194b021. View

Kamath A, Pasteur M, Slade M, Harrison B . Recognising severe pneumonia with simple clinical and biochemical measurements. Clin Med (Lond). 2003; 3(1):54-6. PMC: 4953359. DOI: 10.7861/clinmedicine.3-1-54. View

Feldman C, Ross S, Mahomed A, Omar J, Smith C . The aetiology of severe community-acquired pneumonia and its impact on initial, empiric, antimicrobial chemotherapy. Respir Med. 1995; 89(3):187-92. DOI: 10.1016/0954-6111(95)90246-5. View

. Community-acquired pneumonia in adults in British hospitals in 1982-1983: a survey of aetiology, mortality, prognostic factors and outcome. The British Thoracic Society and the Public Health Laboratory Service. Q J Med. 1987; 62(239):195-220. View

Lisboa T, Blot S, Waterer G, Canalis E, de Mendoza D, Rodriguez A . Radiologic progression of pulmonary infiltrates predicts a worse prognosis in severe community-acquired pneumonia than bacteremia. Chest. 2008; 135(1):165-172. DOI: 10.1378/chest.08-1216. View

10.

Leroy O, Saux P, Bedos J, Caulin E . Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest. 2005; 128(1):172-83. DOI: 10.1378/chest.128.1.172. View

11.

Espana P, Capelastegui A, Gorordo I, Esteban C, Oribe M, Ortega M . Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med. 2006; 174(11):1249-56. DOI: 10.1164/rccm.200602-177OC. View

12.

Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber P . Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006; 174(1):84-93. DOI: 10.1164/rccm.200512-1922OC. View

13.

Gibot S, Cravoisy A, Levy B, Bene M, Faure G, Bollaert P . Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med. 2004; 350(5):451-8. DOI: 10.1056/NEJMoa031544. View

14.

Sprung C, Annane D, Keh D, Moreno R, Singer M, Freivogel K . Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008; 358(2):111-24. DOI: 10.1056/NEJMoa071366. View

15.

Ewig S, Bauer T, Hasper E, Pizzulli L, Kubini R, Luderitz B . Prognostic analysis and predictive rule for outcome of hospital-treated community-acquired pneumonia. Eur Respir J. 1995; 8(3):392-7. DOI: 10.1183/09031936.95.08030392. View

16.

Fine M, Auble T, Yealy D, Hanusa B, Weissfeld L, Singer D . A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997; 336(4):243-50. DOI: 10.1056/NEJM199701233360402. View

17.

Valencia M, Badia J, Cavalcanti M, Ferrer M, Agusti C, Angrill J . Pneumonia severity index class v patients with community-acquired pneumonia: characteristics, outcomes, and value of severity scores. Chest. 2007; 132(2):515-22. DOI: 10.1378/chest.07-0306. View

18.

Salluh J, Povoa P, Soares M, Castro-Faria-Neto H, Bozza F, Bozza P . The role of corticosteroids in severe community-acquired pneumonia: a systematic review. Crit Care. 2008; 12(3):R76. PMC: 2481473. DOI: 10.1186/cc6922. View

19.

Bartolome M, Almirall J, Morera J, Pera G, Ortun V, Bassa J . A population-based study of the costs of care for community-acquired pneumonia. Eur Respir J. 2004; 23(4):610-6. DOI: 10.1183/09031936.04.00076704. View

20.

Riquelme R, Torres A, de la Bellacasa J, Estruch R, Mensa J, Fernandez-Sola J . Community-acquired pneumonia in the elderly: A multivariate analysis of risk and prognostic factors. Am J Respir Crit Care Med. 1996; 154(5):1450-5. DOI: 10.1164/ajrccm.154.5.8912763. View